EPS for Harley-Davidson, Inc. (HOG) Expected At $0.48; Arqule (ARQL) Shorts Down By 6.4%

January 14, 2018 - By Clifton Ray

Arqule Incorporated (NASDAQ:ARQL) had a decrease of 6.4% in short interest. ARQL’s SI was 670,100 shares in January as released by FINRA. Its down 6.4% from 715,900 shares previously. With 229,300 avg volume, 3 days are for Arqule Incorporated (NASDAQ:ARQL)’s short sellers to cover ARQL’s short positions. The SI to Arqule Incorporated’s float is 1.45%. The stock increased 0.55% or $0.01 during the last trading session, reaching $1.83. About 198,307 shares traded. ArQule, Inc. (NASDAQ:ARQL) has declined 22.70% since January 14, 2017 and is downtrending. It has underperformed by 39.40% the S&P500.

Analysts expect Harley-Davidson, Inc. (NYSE:HOG) to report $0.48 EPS on January, 30.They anticipate $0.21 EPS change or 77.78% from last quarter’s $0.27 EPS. HOG’s profit would be $80.13M giving it 28.34 P/E if the $0.48 EPS is correct. After having $0.40 EPS previously, Harley-Davidson, Inc.’s analysts see 20.00% EPS growth. The stock increased 1.45% or $0.78 during the last trading session, reaching $54.41. About 1.96 million shares traded. Harley-Davidson, Inc. (NYSE:HOG) has risen 20.11% since January 14, 2017 and is uptrending. It has outperformed by 3.41% the S&P500.

Among 3 analysts covering ArQule (NASDAQ:ARQL), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. ArQule had 3 analyst reports since December 9, 2015 according to SRatingsIntel. Needham upgraded the stock to “Buy” rating in Thursday, December 14 report. RBC Capital Markets upgraded the shares of ARQL in report on Monday, December 21 to “Outperform” rating. As per Wednesday, December 9, the company rating was reinitiated by Leerink Swann.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company has market cap of $159.41 million. The Company’s lead product candidate is tivantinib , a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. It currently has negative earnings. The companyÂ’s clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death.

Investors sentiment decreased to 0.75 in Q3 2017. Its down 0.16, from 0.91 in 2017Q2. It dived, as 54 investors sold Harley-Davidson, Inc. shares while 151 reduced holdings. 36 funds opened positions while 117 raised stakes. 159.80 million shares or 4.22% more from 153.33 million shares in 2017Q2 were reported. Gotham Asset Management Lc stated it has 379,321 shares. The New York-based Mathes has invested 0.19% in Harley-Davidson, Inc. (NYSE:HOG). Bnp Paribas Asset Mgmt accumulated 9,221 shares. 1,190 were accumulated by Advisory Ser Network Lc. Victory Incorporated, a Ohio-based fund reported 155,064 shares. St Johns Invest Company Lc has invested 0% in Harley-Davidson, Inc. (NYSE:HOG). Raymond James And Assoc owns 31,512 shares. Loring Wolcott Coolidge Fiduciary Advsrs Llp Ma holds 0% of its portfolio in Harley-Davidson, Inc. (NYSE:HOG) for 2,615 shares. Raymond James Services Advisors Incorporated owns 19,246 shares. Lpl Lc owns 24,550 shares or 0% of their US portfolio. Washington Trust Bancorp has 0% invested in Harley-Davidson, Inc. (NYSE:HOG). Kentucky Retirement Sys Ins Tru Fund holds 0.04% or 4,628 shares. Cornerstone Capital Management Holdg Ltd Liability reported 0.01% in Harley-Davidson, Inc. (NYSE:HOG). Centurylink Invest, Colorado-based fund reported 30,683 shares. West Oak Capital Limited Liability Corp stated it has 0.01% of its portfolio in Harley-Davidson, Inc. (NYSE:HOG).

Among 25 analysts covering Harley-Davidson (NYSE:HOG), 5 have Buy rating, 2 Sell and 18 Hold. Therefore 20% are positive. Harley-Davidson had 85 analyst reports since July 22, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets with “Sector Perform” on Monday, January 18. The rating was maintained by Citigroup with “Buy” on Thursday, February 4. The stock has “Market Perform” rating by BMO Capital Markets on Wednesday, October 21. On Wednesday, February 1 the stock rating was maintained by RBC Capital Markets with “Sector Perform”. The rating was downgraded by Longbow on Monday, August 29 to “Underperform”. The company was maintained on Thursday, July 13 by BMO Capital Markets. The stock of Harley-Davidson, Inc. (NYSE:HOG) earned “Neutral” rating by Longbow on Wednesday, March 15. The firm has “Underperform” rating given on Monday, January 11 by Raymond James. The stock of Harley-Davidson, Inc. (NYSE:HOG) earned “Hold” rating by Stifel Nicolaus on Wednesday, October 19. The firm earned “Outperform” rating on Friday, September 9 by Bernstein.

Harley-Davidson, Inc. primarily manufactures and sells cruiser and touring motorcycles. The company has market cap of $9.08 billion. The firm operates through two divisions, Motorcycles & Related Products, and Financial Services. It has a 16.98 P/E ratio. The Motorcycles & Related Products segment designs, makes, and sells wholesale on-road Harley-Davidson motorcycles, as well as motorcycle parts, accessories, general merchandise, and related services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>